Preclinical News and Research

RSS

Novel strategy to tackle acute myelogenous leukemia

A novel strategy to hopefully beat into oblivion one of the most aggressive forms of acute myelogenous leukemia combines the strengths of some of the newest leukemia agents, researchers say.

25 Sep 2007

Spinal Muscular Atrophy Foundation and BG Medicine collaborate

The Spinal Muscular Atrophy Foundation and BG Medicine have announced a collaboration to discover plasma biomarkers of drug efficacy for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.

18 Sep 2007

Oxford Genome Sciences partners with Medarex

Oxford Genome Sciences (UK) Ltd (OGeS) has announced a second partnering agreement with Medarex, Inc.

18 Sep 2007

Helix BioPharma awarded U.S. patent for adjunct chemotherapy applications

Helix BioPharma Corp. has announced the issuance of its second DOS47 patent (U.S. Patent # 7,264,800) from the United States Patent & Trademark Office, describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment applications.

18 Sep 2007

Pregnancy appears to cut risks for HIV-infected women

Women with HIV infection who become pregnant have a lower risk of progression to AIDS and death, researchers at Vanderbilt University Medical Center report.

13 Sep 2007

GeoVax Labs presents successful human trial results for its HIV/AIDS vaccines

GeoVax Labs, Inc. has announced the presentation of successful human trial results for its HIV/AIDS vaccines at the AIDS Vaccine 2007 Conference held August 20-23, 2007 in Seattle, Washington.

13 Sep 2007

No evidence that Aspartame non-nutritive sweetener causes cancer

A sweeping review of research studies of aspartame says there is no evidence that the non-nutritive sweetener causes cancer, neurological damage or other health problems in humans.

12 Sep 2007

Vitamin C inhibits the growth of some tumors

Nearly 30 years after Nobel laureate Linus Pauling famously and controversially suggested that vitamin C supplements can prevent cancer, a team of Johns Hopkins scientists have shown that in mice at least, vitamin C - and potentially other antioxidants - can indeed inhibit the growth of some tumors ¯ just not in the manner suggested by years of investigation.

11 Sep 2007

A molecular probe that may one day light up tumors while surgery is in progress

Researchers at the Stanford University School of Medicine have developed a molecular probe that sets aglow tumor cells within living animals. Their goal is to use the probe to improve the diagnosis and treatment of cancer and other diseases.

10 Sep 2007

Decitabine and interferon gamma show promise for ocular melanoma that has spread

A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.

5 Sep 2007

Ardea Biosciences completes phase 1 trials of HIV drug RDEA806

Ardea Biosciences, Inc. has announced that it has successfully completed Phase 1 single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers.

5 Sep 2007

Novel HIV vaccine set for clinical development

A promising new HIV vaccine created at The Wistar Institute has received funding for clinical development aimed at moving the vaccine into human clinical trials as soon as possible.

3 Sep 2007

The goals of platelet inhibition in acute coronary syndromes

Platelet activation and aggregation play important roles in the pathogenesis of cardiac ischemic events after either spontaneous plaque disruption in acute coronary syndromes or mechanical disruption of coronary artery plaques caused by percutaneous coronary intervention (PCI), which could be considered an artificially induced acute coronary syndrome.

3 Sep 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

Animal model for dengue research

A mosquito-borne disease often known as "break-bone fever" has found a new enemy in a unique type of mouse.

28 Aug 2007

Pfizer and Bristol-Myers Squibb finalize agreement on metabolic disorders program

Pfizer Inc. and Bristol-Myers Squibb Company have announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007.

28 Aug 2007

New options in treating pigmentation disorders

Melanocytes are not the only cells responsible for differences in skin coloration. New research from the University of Cincinnati (UC) has shown that some of the most basic cells on the skin's surface influence pigment production and help regulate skin coloration.

24 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Age-related macular degeneration patient receives investigational eye drops

An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.

17 Aug 2007

Metformin kills some cancer cells

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53.

16 Aug 2007